Hyperplasia News and Research

RSS

Protox' Phase 2 study of PRX302 for treating BPH provides positive results

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced positive 12 month data from its open-label Phase 2 study of PRX302 in males with moderate to severe benign prostatic hyperplasia (BPH). The study results indicate that those patients who received an optimal dose of PRX302 continued to demonstrate significant symptomatic relief at 12 months following a single treatment.

10 Sep 2009

Protox Therapeutics to present TRIUMPH clinical study update

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that Dr. Fahar Merchant, President & CEO of Protox Therapeutics, will present at the 11th Annual Rodman & Renshaw Healthcare Conference.

9 Sep 2009

TURis plasma vaporization electrode for benign prostatic hyperplasia therapy

The TURis plasma vaporization electrode does not cut off tissue with a loop, but energetically vaporizes the tissue with a small button electrode. With the help of the latest plasma technology, cells can be removed by merely gliding the electrode over the prostate tissue.

From Evident Corporation - Life Sciences 9 Sep 2009

Patient enrollment for Phase 2b study of PRX302 completed by Protox Therapeutics

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced that it has completed patient enrollment in its multi-centre, double-blinded, placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in males with moderate to severe benign prostatic hyperplasia (BPH), a common and bothersome urological condition that affects more than 50 million men worldwide.

8 Sep 2009

Urologix announces fiscal 2009 fourth-quarter and full-year financial results

Urologix®, Inc. (NASDAQ:ULGX), a medical device company focused on developing, manufacturing and marketing Cooled ThermoTherapy™ systems, a durable and effective catheter based in-office alternative to drugs or surgery for patients suffering from benign prostatic hyperplasia (BPH), today reported financial results for the fourth quarter ended June 30, 2009 and for fiscal year 2009.

26 Aug 2009

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.

19 Aug 2009

Arzoxifene phase 3 study results reported by Lilly

Eli Lilly and Company announced today that initial results from its pivotal, five-year, Phase III GJAD "GENERATIONS" trial for arzoxifene met its primary endpoints of significantly reducing the risk of vertebral fracture and invasive breast cancer in postmenopausal women.

19 Aug 2009

Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hyperplasia

AEterna Zentaris Inc. today reported Phase 3 results for its North American efficacy trial Z-033 and the safety trial Z-041 in benign prostatic hyperplasia (BPH), with its lead endocrinology compound for urology, cetrorelix pamoate. As announced on March 6, 2009, sanofi-aventis U.S. LLC entered into an agreement with AEterna Zentaris for the development, registration and marketing of cetrorelix in BPH for the U.S. market.

17 Aug 2009

Protein produced by gene fusion that may also be targeted for new prostate cancer therapies

Researchers from NewYork-Presbyterian Hospital/Weill Cornell Medical Center have discovered a new gene fusion that is highly expressed in a subset of prostate cancers.

24 Jul 2009

Discovery of four new breast cancer targets

Four suspects often found at the scene of the crime in cancer are guilty of the initiation and progression of breast cancer in mice that are resistant to the disease, a team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the June edition of Cancer Cell.

10 Jun 2009

Tadalafil may improve lower urinary tract symptoms in men with benign prostatic hyperplasia

Relative symptom improvement in the IPSS also was significantly better in the tadalafil group. At the end of the study, the proportion of obstructed patients in the placebo group increased, while the proportion in the tadalafil group decreased.

26 Apr 2009

Statins may benefit men with prostate cancer, erectile dysfunction or lower urinary tract symptoms

Several new studies presented at the American Urological Association's (AUA) 104th Annual Scientific Meeting suggest that the use of statins - commonly prescribed to lower cholesterol - may benefit men with prostate cancer, erectile dysfunction or lower urinary tract symptoms (LUTS).

26 Apr 2009

A potential therapeutic target for gastric cancer

Gastric cancer (GC) is the fourth most common malignancy and the second most frequent cause of cancer-related death in the world.

20 Apr 2009

AVEO Pharmaceuticals announces findings from novel human-in-mouse cancer model system

AVEO Pharmaceuticals, Inc. has announced findings from its novel human-in-mouse (HIM) cancer model system, in which AVEO successfully created invasive human tumors from primary human breast tissue that develop over time in mice and mimic human tumor behaviors and response.

6 Apr 2009

Bionovo announces publication of positive phase 2 trial results for Menerba

Bionovo, Inc. has announced the online publication of a peer-reviewed article in the journal, Menopause, reporting Menerba(TM) (formerly MF101) is well tolerated, safe and effective for the treatment of vasomotor symptoms (hot flashes and night sweats) associated with menopause.

2 Apr 2009

Bionovo announces publication of positive trial results for Menerba

Bionovo, Inc. has announced the online publication of a peer-reviewed article in the journal, Menopause, reporting Menerba (formerly MF101) is well tolerated, safe and effective for the treatment of vasomotor symptoms (hot flashes and night sweats) associated with menopause.

3 Mar 2009

Women's cancer outcome improved by surgical evaluation

Many women scheduled to undergo hysterectomy for pre-cancerous cell changes actually need a more comprehensive surgery, something they should discuss with a gynecologic oncologist, say researchers at the University of Alabama at Birmingham (UAB).

16 Feb 2009

Researchers identify risk factors for breast cancer in the opposite breast

A preventive procedure to remove the unaffected breast in breast cancer patients with disease in one breast may only be necessary in patients who have high-risk features as assessed by examining the patient's medical history and pathology of the breast cancer, according to researchers at The University of Texas M. D. Anderson Cancer Center.

27 Jan 2009

Thumbs down by experts on plans to make certain meds OTC

Government plans to make certain prescription-only drugs for common problems available over the counter have overwhelmingly been given the thumbs down by healthcare professionals, reveals a survey of readers of the influential Drug and Therapeutics Bulletin ( DTB ).

13 Jan 2009

Atypical hyperplasia increases risk of developing breast cancer

A type of benign breast disease (BBD) known as atypical hyperplasia substantially increases a young woman's risk of developing breast cancer, even if there is no history of breast cancer in her family, say researchers at Mayo Clinic.

14 Dec 2008